← Back to headlines
Wells Fargo Cuts Price Target on Sarepta Therapeutics (SRPT)
Wells Fargo has reduced its price target for Sarepta Therapeutics (SRPT) from $45 to $38.
1 Mar, 09:27 — 1 Mar, 09:27
Sources
Showing 1 of 1 sources
Related Stories
United Natural Foods Q4 Profit Beats Estimates, Revenue Misses
34m ago
Goldman Sachs Raises Oil Price Forecast on Middle East Conflict, Sees Potential $120 Brent
1h ago
Analysts Say Stock Market Can Absorb a 25 Basis Point Fed Rate Hike
2h ago
Iceland's 2027 budget raises mileage fees, tourist levies and bank tax
18h ago